Enhanced Mouse Antibody Discovery

Most FDA-approved therapeutic monoclonal antibodies were discovered using mouse hybridomas. Though mouse antibodies are safe and efficacious, conventional mouse hybridoma platforms are inefficient, capturing <5% of a mouse's B cell repertoire. Efficiency is particularly important for difficult targets, such as checkpoint inhibitors.

GigaGen's highly efficient platform captures full mouse B cell repertoires and then performs ultra-deep repertoire sequencing to discover therapeutic candidates. We then build protein display libraries from the repertoires to rapidly validate binding and function.

Using our technology, a single mouse produces hundreds or thousands of therapeutic candidates. Candidates are then evolved using modern synthetic biology technology and screened again for binding and function. This is our most active area for collaboration, so contact us for more information.